Advertisement

Topics

Modified FOLFIRINOX results in longer disease-free survival in metastatic pancreatic cancer patients compared to gemcitabine

10:00 EST 21 Dec 2018 | 2 Minute Medicine

1. Randomized control trial of patients with metastatic pancreatic adenocarcinoma demonstrates that adjuvant therapy with a modified FOLFIRINOX regimen results in significantly longer disease-free survival and median overall survival rates as compared to traditional gemcitabine therapy. 2. Higher rates of adverse events were noted among patients randomized to the FOLFIRINOX group. Evidence Rating Level: 1 […]

Original Article: Modified FOLFIRINOX results in longer disease-free survival in metastatic pancreatic cancer patients compared to gemcitabine

NEXT ARTICLE

More From BioPortfolio on "Modified FOLFIRINOX results in longer disease-free survival in metastatic pancreatic cancer patients compared to gemcitabine"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...